Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H or ATG for GVHD Prevention in AML or MDS Patients Undergoing Stem Cell Transplantation
NCT00226512Phase 3Withdrawn
- Sponsor
- Hadassah Medical Organization
- Start
- Jul 2004
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of alemtuzumab, antithymocyte globulin in graft-versus-host disease (GVHD), sponsored by Hadassah Medical Organization. Planned start Jul 2004; status: withdrawn.
02
Drugs
alemtuzumabantithymocyte globulin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00226512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226512.